These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15139761)

  • 1. 1-alkyl-4-acylpiperazines as a new class of imidazole-free histamine H(3) receptor antagonists.
    Zaragoza F; Stephensen H; Knudsen SM; Pridal L; Wulff BS; Rimvall K
    J Med Chem; 2004 May; 47(11):2833-8. PubMed ID: 15139761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D-amino acid homopiperazine amides: discovery of A-320436, a potent and selective non-imidazole histamine H(3)-receptor antagonist.
    Curtis MP; Dwight W; Pratt J; Cowart M; Esbenshade TA; Krueger KM; Fox GB; Pan JB; Pagano TG; Hancock AA; Faghih R; Bennani YL
    Arch Pharm (Weinheim); 2004 Apr; 337(4):219-29. PubMed ID: 15146898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
    Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.
    Zaragoza F; Stephensen H; Peschke B; Rimvall K
    J Med Chem; 2005 Jan; 48(1):306-11. PubMed ID: 15634025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
    J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists.
    Dvorak CA; Apodaca R; Barbier AJ; Berridge CW; Wilson SJ; Boggs JD; Xiao W; Lovenberg TW; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):2229-38. PubMed ID: 15771465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists.
    Walczyński K; Zuiderveld OP; Timmerman H
    Eur J Med Chem; 2005 Jan; 40(1):15-23. PubMed ID: 15642406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines.
    Apodaca R; Dvorak CA; Xiao W; Barbier AJ; Boggs JD; Wilson SJ; Lovenberg TW; Carruthers NI
    J Med Chem; 2003 Aug; 46(18):3938-44. PubMed ID: 12930154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
    Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
    J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
    Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
    Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The first potent and selective non-imidazole human histamine H4 receptor antagonists.
    Jablonowski JA; Grice CA; Chai W; Dvorak CA; Venable JD; Kwok AK; Ly KS; Wei J; Baker SM; Desai PJ; Jiang W; Wilson SJ; Thurmond RL; Karlsson L; Edwards JP; Lovenberg TW; Carruthers NI
    J Med Chem; 2003 Sep; 46(19):3957-60. PubMed ID: 12954048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligands of the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type.
    Plazzi PV; Mor M; Bordi F; Silva C; Rivara S; Caretta A; Ballabeni V; Impicciatore M; Vitali T
    Farmaco; 1997 May; 52(5):295-302. PubMed ID: 9274000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
    Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.
    von Coburg Y; Kottke T; Weizel L; Ligneau X; Stark H
    Bioorg Med Chem Lett; 2009 Jan; 19(2):538-42. PubMed ID: 19091563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.